Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H22N2O3 |
| Molecular Weight | 338.4003 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C1\C[C@@H](CO)N(C1)C(=O)C2=CC=C(C=C2)C3=C(C)C=CC=C3
InChI
InChIKey=OLUJSZLBWZWGJT-HGBKYHTQSA-N
InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1
Erlosiban (OBE-001 or Nolasiban) is an oral oxytocin receptor antagonist. Erlosiban inhibits myometrium contractions and inflammation elicited by oxytocin. Erlosiban has the potential to decrease contractions and improve uterine blood flow hence enhancing the receptivity of the endometrium to embryo implantation. This may increase the rates of successful implantation, clinical pregnancy, and live-births among patients undergoing ART, or more specifically IVF procedures.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P30559 Gene ID: 5021.0 Gene Symbol: OXTR Target Organism: Homo sapiens (Human) Sources: http://www.obseva.com/pipeline/nolasiban |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium. | 2019-04-08 |
|
| Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium. | 2017-04 |
|
| Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats. | 2016-04 |
|
| Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. | 2015-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.obseva.com/pipeline/nolasiban
Phase III trials: 900 mg nolasiban as a single dose increased ongoing pregnancy and live birth rates
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000176871
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY | |||
|
10026
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY | |||
|
3765U8A1EC
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY | |||
|
52947354
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY | |||
|
C166647
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY | |||
|
1477482-19-1
Created by
admin on Mon Mar 31 18:46:34 GMT 2025 , Edited by admin on Mon Mar 31 18:46:34 GMT 2025
|
PRIMARY |
ACTIVE MOIETY